Abbott just announced that it is the first company to receive European regulatory approval to introduce transcatheter mitral valve replacement procedures on the continent. The Tendyne Transcatheter Mitral Valve Implantation (TMVI) system is intended for mitral regurgitation patients for whom open-heart surgery is too risky and in cases where t (Read more...)